No disease recurrences after short course of neoadjuvant immunotherapy, according to follow-up

Long-term follow-up of NICHE-2 shows no recurrences among all 111 patients in the primary efficacy population with dMMR colon cancer treated with neoadjuvant nivolumab plus ipilimumab. In the single-arm, multicenter phase 2 study, patients received two cycles over about four weeks before surgery. The prior pathological response rate was 98% and the pathological complete response rate was 68%. With a median postoperative follow-up of 58.7 months, 3-year disease-free survival and estimated 5-year overall survival were both 100%, and all patients were alive at the most recent follow-up.